Pricing Availability   Qty
Description: Potent inhibitor of PDGFRβ, KDR, FLT3 and CSF-1R
Chemical Name: N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea
Purity: ≥98% (HPLC)
Literature (1)

Biological Activity for Linifanib

Linifanib is a potent receptor tyrosine kinase (RTK) inhibitor. It inhibits PDGFRβ, KDR, FLT3, CSF-1R (IC50 values are 2, 4, 4 and 7 nM, respectively). Linifanib inhibits angiogenesis in vascularized micro-organs and potently inhibits VEGF-stimulated endothelial cell proliferation (IC50 = 0.2 nM). Linifanib also promotes the generation and reprogramming of iPSCs from somatic cells.

Technical Data for Linifanib

M. Wt 375.4
Formula C21H18FN5O
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 796967-16-3
PubChem ID 11485656
Smiles O=C(NC=1C=CC(=CC1)C=2C=CC=C3NN=C(N)C32)NC4=CC(=CC=C4F)C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for Linifanib

Solvent Max Conc. mg/mL Max Conc. mM
ethanol 7.51 20
DMSO 37.54 100

Preparing Stock Solutions for Linifanib

The following data is based on the product molecular weight 375.4. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.66 mL 13.32 mL 26.64 mL
5 mM 0.53 mL 2.66 mL 5.33 mL
10 mM 0.27 mL 1.33 mL 2.66 mL
50 mM 0.05 mL 0.27 mL 0.53 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for Linifanib

References are publications that support the biological activity of the product.

Albert et al (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol.Cancer Ther. 5 995 PMID: 16648571

Guan et al (2022) Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature 605 325 PMID: 35418683

Jahid et al (2022) Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer. Cell Rep. 39 110641 PMID: 35385746

If you know of a relevant reference for Linifanib, please let us know.

View Related Products by Product Action

View all PDGFR Inhibitors

Keywords: Linifanib, Linifanib supplier, receptor, tyrosine, kinases, inhibitors, potent, vegfr, pdgfr, angiogeneis, stem, cells, reprogramming, iPSC, PDGFR, VEGFR, Stem, Cell, Reprogramming, 7743, Tocris Bioscience

Citations for Linifanib

Citations are publications that use Tocris products.

Currently there are no citations for Linifanib. Do you know of a great paper that uses Linifanib from Tocris? Please let us know.

Reviews for Linifanib

There are currently no reviews for this product. Be the first to review Linifanib and earn rewards!

Have you used Linifanib?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Angiogenesis in Cancer Poster

Angiogenesis in Cancer Poster

This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.